文献速递骨质疏松与钙磷/甲状旁腺

维生素D补充预防急性呼吸道感染:随机对照试验聚合数据的系统综述与荟萃分析

Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-03-30

补充维生素D未增加严重不良事件风险。

要点

  • 每日给药、每日400-1000 IU、补充≤12个月及1-15岁人群显示保护作用。
  • 未观察到补充维生素D增加严重不良事件风险。

核心结论

  • 维生素D补充总体安全且小幅降低急性呼吸道感染风险,但研究间存在显著异质性。
  • 基线25(OH)D浓度各亚组均未观察到维生素D补充对急性呼吸道感染风险的显著影响。
  • 该研究结果对COVID-19的相关性尚不明确,需进一步研究。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane中央对照试验注册库、Web of Science及ClinicalTrials.gov,从数据库建立至2020年5月1日。
  • 纳入双盲随机对照试验,干预为维生素D3、维生素D2或25-羟基维生素D补充,对照为安慰剂或低剂量维生素D,任何持续时间。
  • 采用随机效应荟萃分析计算合并比值比(OR)及95%置信区间(CI)。

临床怎么用

  • 对于1-15岁儿童和青少年,可考虑每日补充维生素D 400-1000 IU以小幅降低急性呼吸道感染风险。
  • 每日给药方案可能优于间歇大剂量方案,但需结合患者具体情况个体化决策。
  • 补充维生素D未增加严重不良事件风险,安全性良好。
  • 不应将本研究结果直接外推至COVID-19预防,需等待进一步研究。

局限性

  • 基线25(OH)D浓度各亚组均未显示显著效果,提示保护作用机制尚不明确。
  • 研究结果对COVID-19的相关性未知。
  • 仅3项试验外的偏倚风险评估为低风险,其余试验偏倚风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A 2017 meta-analysis of data from 25 randomised controlled trials (RCTs) of vitamin D supplementation for the prevention of acute respiratory infections (ARIs) revealed a protective effect of this intervention. We aimed to examine the link between vitamin D supplementation and prevention of ARIs in an updated meta-analysis. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov registry for studies listed from database inception to May 1, 2020. Double-blind RCTs of vitamin D3, vitamin D2, or 25-hydroxyvitamin D (25[OH]D) supplementation for any duration, with a placebo or low-dose vitamin D control, were eligible if they had been approved by a research ethics committee, and if ARI incidence was collected prospectively and prespecified as an efficacy outcome. Studies reporting results of long-term follow-up of primary RCTs were excluded. Aggregated study-level data, stratified by baseline 25(OH)D concentration and age, were obtained from study authors. Using the proportion of participants in each trial who had one or more ARIs, we did a random-effects meta-analysis to obtain pooled odds ratios (ORs) and 95% CIs to estimate the effect of vitamin D supplementation on the risk of having one or more ARIs (primary outcome) compared with placebo. Subgroup analyses were done to estimate whether the effects of vitamin D supplementation on the risk of ARI varied according to baseline 25(OH)D concentration (<25 nmol/L vs 25·0-49·9 nmol/L vs 50·0-74·9 nmol/L vs >75·0 nmol/L), vitamin D dose (daily equivalent of <400 international units [IU] vs 400-1000 IU vs 1001-2000 IU vs >2000 IU), dosing frequency (daily vs weekly vs once per month to once every 3 months), trial duration (≤12 months vs >12 months), age at enrolment (<1·00 years vs 1·00-15·99 years vs 16·00-64·99 years vs ≥65·00 years), and presence versus absence of airway disease (ie, asthma only, COPD only, or unrestricted). Risk of bias was assessed with the Cochrane Collaboration Risk of Bias Tool. The study was registered with PROSPERO, CRD42020190633. FINDINGS: We identified 1528 articles, of which 46 RCTs (75 541 participants) were eligible. Data for the primary outcome were obtained for 48 488 (98·1%) of 49 419 participants (aged 0-95 years) in 43 studies. A significantly lower proportion of participants in the vitamin D supplementation group had one or more ARIs (14 332 [61·3%] of 23 364 participants) than in the placebo group (14 217 [62·3%] of 22 802 participants), with an OR of 0·92 (95% CI 0·86-0·99; 37 studies; I2=35·6%, pheterogeneity=0·018). No significant effect of vitamin D supplementation on the risk of having one or more ARIs was observed for any of the subgroups defined by baseline 25(OH)D concentration. However, protective effects of supplementation were observed in trials in which vitamin D was given in a daily dosing regimen (OR 0·78 [95% CI 0·65-0·94]; 19 studies; I2=53·5%, pheterogeneity=0·003), at daily dose equivalents of 400-1000 IU (0·70 [0·55-0·89]; ten studies; I2=31·2%, pheterogeneity=0·16), for a duration of 12 months or less (0·82 [0·72-0·93]; 29 studies; I2=38·1%, pheterogeneity=0·021), and to participants aged 1·00-15·99 years at enrolment (0·71 [0·57-0·90]; 15 studies; I2=46·0%, pheterogeneity=0·027). No significant interaction between allocation to the vitamin D supplementation group versus the placebo group and dose, dose frequency, study duration, or age was observed. In addition, no significant difference in the proportion of participants who had at least one serious adverse event in the vitamin supplementation group compared with the placebo group was observed (0·97 [0·86-1·07]; 36 studies; I2=0·0%, pheterogeneity=0·99). Risk of bias within individual studies was assessed as being low for all but three trials. INTERPRETATION: Despite evidence of significant heterogeneity across trials, vitamin D supplementation was safe and overall reduced the risk of ARI compared with placebo, although the risk reduction was small. Protection was associated with administration of daily doses of 400-1000 IU for up to 12 months, and age at enrolment of 1·00-15·99 years. The relevance of these findings to COVID-19 is not known and requires further investigation. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Jolliffe DA, Camargo CA, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021. PMID: 33798465. doi:10.1016/S2213-8587(21)00051-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。